A BILL FOR AN ACT

RELATING TO HEALTH.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

- 1 SECTION 1. The legislature finds that pharmacies are vital
- 2 to the State's health care system because of their convenient
- 3 points of access in their communities. Pharmacists are trusted
- 4 health care professionals who have established relationships
- 5 with their patients, medical providers, and hospitals.
- 6 The legislature further finds that the coronavirus disease
- 7 2019 (COVID-19) pandemic highlighted the critical need to
- 8 address health care testing accessibility and streamline
- 9 unnecessary administrative regulations. To increase COVID-19
- 10 testing, in April 2020, the federal government issued an
- 11 emergency declaration under the Public Readiness and Emergency
- 12 Preparedness (PREP) Act, which, among other things, authorized
- 13 pharmacists to order and administer COVID-19 testing and
- 14 increased access to certain pharmacy-administered tests. The
- 15 PREP Act is in effect through the end of 2024; however, there
- 16 are certain provisions in the PREP Act that have not been
- 17 codified in state law.



S.B. NO. 502 S.D. 2 H.D. 1

- 1 In addition to COVID-19 tests, the legislature further
- 2 finds that pharmacists in the State are currently permitted to
- 3 perform certain drug therapy-related tests under the definition
- 4 of "practice of pharmacy" in section 461-1, Hawaii Revised
- 5 Statutes. However, there are differing interpretations under
- 6 state law as to whether pharmacists can explicitly perform tests
- 7 that are classified as waived under the federal Clinical
- 8 Laboratory Improvement Amendments of 1988 (CLIA). CLIA-waived
- 9 tests are simple tests that are non-technical and have a low
- 10 risk for erroneous results. Some examples of CLIA-waived tests
- 11 include blood glucose monitoring tests, streptococcal
- 12 pharyngitis tests, cholesterol monitoring tests, and various
- 13 tests for respiratory illnesses including influenza and
- 14 respiratory syncytial virus, and, recently, SARS-CoV-2 (COVID-
- 15 19) point-of-care or "rapid" tests.
- 16 Accordingly, the purpose of this Act is to amend the
- 17 pharmacy scope of practice to specify that pharmacists may
- 18 order, perform, and report the results of certain CLIA-waived
- 19 tests.

1	SECT	ION 2. Chapter 461, Hawaii Revised Statutes, is
2	amended b	y adding a new section to be appropriately designated
3	and to re	ad as follows:
4	" <u>§46</u>	1- CLIA-waived tests; authority; permitting and
5	education	requirements; reporting. (a) Unless otherwise
6	authorize	d by law, a pharmacist shall only exercise the
7	authority	granted under paragraph (5) of the definition of
8	"practice	of pharmacy" in section 461-1 to order, perform, and
9	report th	e results of certain CLIA-waived tests:
10	(1)	After completing appropriate training that includes
11		programs approved by the Accreditation Council for
12		Pharmacy Education, curriculum-based programs from an
13		Accreditation Council for Pharmacy Education-
14		accredited college of pharmacy, state or local health
15		department programs, or programs recognized by the
16		board, and any regulations promulgated by the federal
17		Centers for Medicare and Medicaid Services; and
18	(2)	Upon application for and receipt of a permit pursuant
19		to the requirements of section 321-13.
20	(b)	Any pharmacist performing a CLIA-waived test for a
21	patient s	hall report the results of the test to a minor

- 1 patient's pediatrician or an adult patient's primary care
- 2 provider, if such information is provided by the patient at the
- 3 time of testing. The pharmacist shall attempt to solicit
- 4 pediatrician or primary care provider information at the time of
- 5 performing the CLIA-waived test.
- 6 (c) For any CLIA-waived tests performed, pharmacists shall
- 7 follow all applicable state laws and rules regarding the
- 8 reporting of diseases."
- 9 SECTION 3. Section 461-1, Hawaii Revised Statutes, is
- 10 amended as follows:
- 1. By adding a new definition to be appropriately inserted
- 12 and to read:
- ""CLIA-waived tests" means any test that is classified as
- 14 waived under the federal Clinical Laboratory Improvement
- 15 Amendments of 1988 (42 U.S.C. 263a)."
- 16 2. By amending the definition of "practice of pharmacy" to
- 17 read:
- ""Practice of pharmacy" means:
- 19 (1) The interpretation and evaluation of prescription
- orders; the compounding, dispensing, and labeling of
- 21 drugs and devices (except labeling by a manufacturer,

1		packer, or distributor of nonprescription drugs and
2		commercially legend drugs and devices); the
3		participation in drug selection and drug utilization
4		reviews; the proper and safe storage of drugs and
5		devices and the maintenance of proper records
6		therefor; the responsibility for advising when
7		necessary or where regulated, of therapeutic values,
8		content, hazards, and use of drugs and devices; and
9		the interpretation and evaluation of prescription
10		orders to adjust the supply dispensed for purposes of
11		medication synchronization pursuant to section
12		431:10A-606, 432:1-621, or 432D-30;
13	(2)	Performing the following procedures or functions as
14		part of the care provided by and in concurrence with a
15		"health care facility" and "health care service" as
16		defined in section 323D-2; or a "pharmacy"; or a
17		licensed physician, a licensed physician assistant, or
18		a licensed advanced practice registered nurse with
19		prescriptive authority; or a "managed care plan" as
20		defined in section 432E-1, in accordance with
21		policies, procedures, or protocols developed

1	COLI	aboractively by hearth professionars, including
2	phys	sicians and surgeons, pharmacists, physician
3	assi	stants, and registered nurses, and for which a
4	phar	macist has received appropriate training required
5	by t	hese policies, procedures, or protocols:
6	(A)	Ordering or performing routine drug therapy
7		related patient assessment procedures;
8	(B)	Ordering drug therapy related laboratory tests;
9	(C)	Initiating emergency contraception oral drug
10		therapy in accordance with a written
11		collaborative agreement approved by the board,
12		between a licensed physician, physician
13		assistant, or advanced practice registered nurse
14		with prescriptive authority and a pharmacist who
15		has received appropriate training that includes
16		programs approved by the Accreditation Council
17		for Pharmacy Education (ACPE), curriculum-based
18		programs from an ACPE-accredited college of
19		pharmacy, state or local health department
20		programs, or programs recognized by the board [of
21		pharmacy];

1	(D)	Administering drugs orally, topically, by
2		intranasal delivery, or by injection, pursuant to
3		the order of the patient's licensed physician,
4		physician assistant, or advanced practice
5		registered nurse with prescriptive authority, by
6		a pharmacist having appropriate training that
7		includes programs approved by the ACPE,
8		curriculum-based programs from an ACPE-accredited
9		college of pharmacy, state or local health
10		department programs, or programs recognized by
11		the board [of pharmacy];
12	(E)	Administering:
13		(i) Immunizations orally, by injection, or by
14		intranasal delivery, to persons eighteen
15		years of age or older by a pharmacist having
16		appropriate training that includes programs
17		approved by the ACPE, curriculum-based
18		programs from an ACPE-accredited college of
19		pharmacy, state or local health department
20		programs, or programs recognized by the
21		board [of pharmacy];

1	(II) vaccines to persons between rourteen and
2	seventeen years of age pursuant to section
3	461-11.4; and
4	(iii) Human papillomavirus, Tdap (tetanus,
5	diphtheria, pertussis), meningococcal, and
6	influenza vaccines to persons between eleven
7	and seventeen years of age pursuant to
8	section 461-11.4;
9	(F) As authorized by the written instructions of a
10	licensed physician, physician assistant, or
11	advanced practice registered nurse with
12	prescriptive authority, initiating or adjusting
13	the drug regimen of a patient pursuant to an
14	order or authorization made by the patient's
15	licensed physician, physician assistant, or
16	advanced practice registered nurse with
17	prescriptive authority and related to the
18	condition for which the patient has been seen by
19	the licensed physician, physician assistant, or
20	advanced practice registered nurse with
21	prescriptive authority; provided that the

1			pharmacist shall issue written notification to
2			the patient's licensed physician, physician
3			assistant, or advanced practice registered nurse
4			with prescriptive authority or enter the
5			appropriate information in an electronic patient
6			record system shared by the licensed physician,
7			physician assistant, or advanced practice
8			registered nurse with prescriptive authority,
9			within twenty-four hours;
10		(G)	Transmitting a valid prescription to another
11			pharmacist for the purpose of filling or
12			dispensing;
13		(H)	Providing consultation, information, or education
14			to patients and health care professionals based
15			on the pharmacist's training and for which no
16			other licensure is required; or
17		(I)	Prescribing and dispensing an opioid antagonist
18			pursuant to section 461-11.8;
19	(3)	The	offering or performing of those acts, services,
20		oper	ations, or transactions necessary in the conduct,
21		oper	ation, management, and control of pharmacy; [and]

1	(4)	Prescribing and dispensing contraceptive supplies
2		pursuant to section 461-11.6[-]; and
3	(5)	Notwithstanding any other law to the contrary, and in
4		accordance with the requirements of section 461- ,
5		ordering, performing, and reporting the results of the
6		following CLIA-waived tests:
7		(A) Blood glucose;
8		(B) Hemoglobin AlC;
9		(C) Hepatitis C;
10		(D) Human immunodeficiency virus;
11		(E) Influenza;
12		(F) Respiratory syncytial virus;
13		(G) SARS-CoV-2; or
14		(H) Streptococcal pharyngitis."
15	SECT	ION 4. Statutory material to be repealed is bracketed
16	and stric	ken. New statutory material is underscored.
17	SECT	ION 5. This Act shall take effect upon its approval.

Report Title:

Pharmacy Scope of Practice; CLIA-Waived Tests; Pharmacists; Permit; Education Requirements; Reporting Requirements

Description:

Authorizes pharmacists to order, perform, and report the results of certain Clinical Laboratory Improvement Amendments of 1988-waived tests. Specifies educational and permitting requirements for the ordering, performance, and reporting the results of certain CLIA-waived tests. (CD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.